SEC Form 4 · accession 0001567619-18-001878
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A Meier
Director
Period of report
Aug 27, 2018
Accepted (ET)
Aug 29, 2018 · 3:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 27, 2018 | M | 13,000 | $14.39 | A | 69,610 | D | |
| Common Stock | Aug 27, 2018 | M | 2,000 | $14.39 | A | 71,610 | D | |
| Common StockF1 | Aug 27, 2018 | S | 2,000 | $100.1177 | D | 69,610 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F2 | $14.39 | Aug 27, 2018 | M | 2,000 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 2,000 | 13,000 | D |
| Stock Option (Right to buy Common Stock)F2 | $14.39 | Aug 27, 2018 | M | 13,000 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 13,000 | 0 | D |
Explanation of responses
- F1The price in column 4 is the weighted average price. The price actually received ranged from $100.112 to $100.130. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F2Reflects the number of options outstanding after the transactions from this specific stock option grant.